Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Targeted Oncology
Published in: Targeted Oncology 3/2018

01-06-2018 | Adis Drug Evaluation

Atezolizumab: A Review in Previously Treated Advanced Non-Small Cell Lung Cancer

Author: Hannah A. Blair

Published in: Targeted Oncology | Issue 3/2018

Login to get access

Abstract

Atezolizumab (TECENTRIQ™), an immune checkpoint inhibitor, is an immunoglobulin G1 monoclonal antibody that binds to programmed death ligand 1 (PD-L1) and blocks its interactions with programmed death 1 and B7.1 receptors. Atezolizumab is approved as monotherapy in several countries worldwide for the treatment of patients with advanced non-small cell lung cancer (NSCLC) who have previously received chemotherapy. Approval was based on its clinical benefit in this setting in the phase II POPLAR and phase III OAK trials. In these studies, atezolizumab significantly prolonged overall survival (OS) relative to docetaxel, regardless of PD-L1 status. Increasing PD-L1 expression was associated with OS improvements. Atezolizumab also demonstrated efficacy in the phase II FIR and BIRCH trials, as assessed by objective response rates (ORRs) in patients with tumours expressing PD-L1. Higher ORRs were seen in patients with high PD-L1 expression. Atezolizumab had an acceptable, manageable tolerability profile, with a low incidence of immune-related adverse events. Therefore, atezolizumab is a valuable treatment option for patients with advanced NSCLC that has progressed during or after chemotherapy.
Literature
1.
2.
3.
Alsaab HO, Sau S, Alzhrani R, et al. PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome. Front Pharmacol. 2017;8:561.CrossRefPubMedPubMedCentral
4.
Chen DS, Irving BA, Hodi FS. Molecular pathways: next-generation immunotherapy--inhibiting programmed death-ligand 1 and programmed death-1. Clin Cancer Res. 2012;18(24):6580–7.CrossRefPubMed
5.
6.
7.
Pharmaceuticals and Medical Devices Agency. Atezolizumab (TECENTRIQ®) intravenous drip infusion 1200 mg: Japanese prescribing information. 2018. http://​www.​pmda.​go.​jp. Accessed 7 May 2018.
8.
9.
Fehrenbacher L, Spira A, Ballinger M, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet. 2016;387(10030):1837–46.CrossRefPubMed
10.
Herbst RS, Soria JC, Kowanetz M, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515(7528):563–7.CrossRefPubMedPubMedCentral
11.
12.
Mizugaki H, Yamamoto N, Murakami H, et al. Phase I dose-finding study of monotherapy with atezolizumab, an engineered immunoglobulin monoclonal antibody targeting PD-L1, in Japanese patients with advanced solid tumors. Investig New Drugs. 2016;34(5):596–603.CrossRef
13.
Gordon MS, Herbst RS, Horn L, et al. Long-term safety and clinical activity of atezolizumab monotherapy in metastatic NSCLC: final results from a phase Ia study [abstract no. PS01.62]. J Thorac Oncol. 2016;11(11 Suppl):S309–S10.CrossRefPubMed
14.
Horn L, Spigel DR, Gettinger SN, et al. Clinical activity, safety and predictive biomarkers of the engineered antibody MPDL3280A (anti-PDL1) in non-small cell lung cancer (NSCLC): update from a phase Ia study [abstract no. 8029]. J Clin Oncol. 2015;33(15 Suppl.).
15.
Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017;389(10066):255–65.CrossRefPubMed
16.
Spigel DR, Chaft JE, Gettinger SN, et al. Clinical activity and safety from a phase II study (FIR) of MPDL3280A (anti-PDL1) in PD-L1-selected patients with non-small cell lung cancer (NSCLC) [abstract no. 8028]. J Clin Oncol. 2015;33(15 Suppl.).
17.
Peters S, Gettinger S, Johnson ML, et al. Phase II trial of atezolizumab as first-line or subsequent therapy for patients with programmed death-ligand 1-selected advanced non-small-cell lung cancer (BIRCH). J Clin Oncol. 2017;35(24):2781–9.CrossRefPubMedPubMedCentral
18.
Park K, Lewanski C. Gadgeel S, et al. 3-year survival and duration of response in randomized phase II study of atezolizumab vs docetaxel in 2L/3L NSCLC (POPLAR) [abstract no. MA 10.03 plus oral presentation]. J Thorac Oncol. 2017;12(11 Suppl. 2):S1840.CrossRef
19.
Satouchi M, Fehrenbacher L, Cobo Dols M, et al. Long-term survival in atezolizumab-treated patients with 2L+ NSCLC from ph III randomized OAK study [abstract no. OA 17.07 plus oral presentation]. J Thorac Oncol. 2017;12(11 Suppl. 2):S1794.CrossRef
20.
Cortinovis D, Gadgeel S, Rittmeyer A, et al. Results from OAK subgroup analyses: a randomized phase III study of atezolizumab vs docetaxel in patients (pts) with advanced NSCLC [abstract no. 89PD]. Ann Oncol. 2017;28(Suppl. 2):ii28–51.
21.
De Marinis F, Barlesi F, Rittmeyer A, et al. Survival and safety of atezolizumab by best overall response (BOR) in the phase III NSCLC OAK study [abstract no. 1310P plus poster]. Ann Oncol. 2017;28(Suppl. 5):467.
22.
Gandara D, Von Pawel J, Sullivan S, et al. Impact of atezolizumab (atezo) treatment beyond disease progression (TBP) in advanced NSCLC: results from the randomized phase III OAK study [abstract no. 9001 plus oral presentation]. J Clin Oncol. 2017;35(15 Suppl)
23.
Artal-Cortes A, Mazieres J, Fehrenbacher L, et al. Evaluation of non-classical response by immune-modified RECIST and efficacy of atezolizumab beyond disease progression in advanced NSCLC: results from the randomized phase II study POPLAR [abstract no. 96PD_PR]. Ann Oncol. 2017;28(Suppl. 2):35.
24.
Gadgeel S, Kowanetz M, Zou W, et al. Clinical efficacy of atezolizumab (atezo) in PD-L1 subgroups defined by SP142 and 22C3 IHC assays in 2L+ NSCLC: results from the randomized OAK study [abstract no. 1296O]. Ann Oncol. 2017;28(Suppl. 5):v460–v96.
25.
Kowanetz M, Zou W, Shames D, et al. Tumor mutation burden (TMB) is associated with improved efficacy of atezolizumab in 1L and 2L+ NSCLC patients [abstract no. OA20.01]. J Thorac Oncol. 2017;12(1 Suppl):S321–S2.CrossRef
26.
27.
Paracha N, Felizzi F. Rate of hospitalization due to adverse event and length of stay for atezolizumab in second and third line metastatic non-small lung cancer (NSCLC) using phase 3 OAK study [abstract no. PCN194]. Value Health. 2017;20:A447.CrossRef
28.
Cortinovis D, von Pawel J, Syrigos K, et al. Immune-related adverse events (irAEs) in advanced NSCLC patients treated with atezolizumab: safety population analyses from the ph III study OAK [abstract no. 1313P plus poster]. Ann Oncol. 2017;28(Suppl. 5):468.
29.
von Pawel J, Syrigos K, Mazieres J, et al. Association between immune-related adverse events (irAEs) and atezolizumab efficacy in advanced NSCLC: analyses from the phase III study OAK [abstract no. 1314P plus poster]. Ann Oncol. 2017;28(Suppl. 5):469.
30.
Lukas R. Safety and efficacy analyses of atezolizumab in advanced non-small cell lung cancer (NSCLC) patients with or without baseline brain metastases [abstract no. 81O]. Ann Oncol. 2017;28(Suppl. 2):ii28–51.
31.
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: non-small cell lung cancer v 3.2018. 2018. http://​www.​nccn.​org. Accessed 7 May 2018.
32.
National Institute for Health and Care Excellence. Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy. 2018. https://​www.​nice.​org.​uk. Accessed 7 May 2018.
33.
Hodi FS, Ballinger M, Lyons B, et al. Immune-modified response evaluation criteria in solid tumors (imRECIST): refining guidelines to assess the clinical benefit of cancer immunotherapy. J Clin Oncol. 2018;36(9):850–8.CrossRefPubMed
34.
Haanen JBAG, Carbonnel F, Robert C, et al. Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(Suppl. 4):iv119–42.CrossRefPubMed
35.
Crequit P, Chaimani A, Yavchitz A, et al. Comparative efficacy and safety of second-line treatments for advanced non-small cell lung cancer with wild-type or unknown status for epidermal growth factor receptor: a systematic review and network meta-analysis. BMC Med. 2017;15(1):193.CrossRefPubMedPubMedCentral
36.
Passiglia F, Galvano A, Rizzo S, et al. Looking for the best immune-checkpoint inhibitor in pre-treated NSCLC patients: an indirect comparison between nivolumab, pembrolizumab and atezolizumab. Int J Cancer. 2018;142(6):1277–84.CrossRefPubMed
37.
Tan PS, Aguiar P Jr, Haaland B, et al. Comparative effectiveness of immune-checkpoint inhibitors for previously treated advanced non-small cell lung cancer – a systematic review and network meta-analysis of 3024 participants. Lung Cancer. 2018;115:84–8.CrossRefPubMed
38.
39.
Kourkoulas N, Kyriopoulos D, Athanasakis K. Cost-effectiveness analysis of atezolizumab compared to the standard of care for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy in Greece [abstract no. PCN150]. Value Health. 2017;20:A439.CrossRef
40.
Kourkoulas N, Kyriopoulos D, Athanasakis K. Budget impact of atezolizumab for the treatment of 2nd line non-small cell lung cancer (NSCLC) after failure with platinum containing chemotherapy in Greece [abstract no. PCN67]. Value Health. 2017;20:A423–4.CrossRef
Metadata
Title
Atezolizumab: A Review in Previously Treated Advanced Non-Small Cell Lung Cancer
Author
Hannah A. Blair
Publication date
01-06-2018
Publisher
Springer International Publishing
Published in
Targeted Oncology / Issue 3/2018
Print ISSN: 1776-2596
Electronic ISSN: 1776-260X
DOI
https://doi.org/10.1007/s11523-018-0570-5

Other articles of this Issue 3/2018

Targeted Oncology 3/2018 Go to the issue

Original Research Article

Prognostic Impact of the Components of Progressive Disease on Survival After First-Line Tyrosine Kinase Inhibitor Therapy for Metastatic Renal Cell Carcinoma

Review Article

The Role of Mesothelin as a Diagnostic and Therapeutic Target in Pancreatic Ductal Adenocarcinoma: A Comprehensive Review

Review Article

Medical Treatment Options for Patients with Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer Suffering from Brain Metastases and/or Leptomeningeal Disease

Original Research Article

Atezolizumab in Metastatic Urothelial Carcinoma Outside Clinical Trials: Focus on Efficacy, Safety, and Response to Subsequent Therapies

Review Article

Prognostic and Predictive Factors for Renal Cell Carcinoma

Original Research Article

Discovery of a Potent and Mutant-Selective EGFR Inhibitor that Overcomes T790M-Mediated Resistance in Lung Cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits